• 1. Oral and Maxillofacial Surgery, People’s Hospital of Anshun City Guizhou Province, Anshun, Guizhou 561000, P. R. China;
  • 2. Stomatology, Suining Central Hospital, Suining, Sichuan 629000, P. R. China;
GUO Lijuan, Email: 663418587@qq.com
Export PDF Favorites Scan Get Citation

Icariin(ICA) is one of the main active ingredients in the Berberidaceae family Epimedium. It makes a variety of biological activities, such as promoting bone formation, antibacterial and anti-inflammatory, and regulating immunity. Periodontitis is a chronic inflammatory disease that is present in the soft and hard tissues of the periodontium. The ultimate goals of its treatment are the reconstruction of periodontal tissues and bone defect repairing. At present, conventional treatment of periodontitis fails to achieve the ideal periodontal tissue regeneration. In recent years, the rapid development of tissue engineering technology has brought new ideas for the treatment of periodontal disease and bone defect repairing. Because of its anti-inflammatory and osteogenic effects, ICA has great potential for the treatments of periodontitis and bone defect repairing. This paper summarizes the effect and the molecular mechanism of ICA in the treatment of periodontitis and bone defect repairing, and discusses its application prospect as a drug for periodontal adjuvant therapy. This paper aims to provide a theoretical basis for the research and application of ICA in periodontitis treatment and bone defect repairing.

Citation: ZHOU Ziqi, YANG Sen, GUO Lijuan. Research progress of icariin in the treatment of periodontitis and bone defect repairing. West China Medical Journal, 2022, 37(1): 140-145. doi: 10.7507/1002-0179.202006226 Copy

  • Previous Article

    Progress in laboratory detection of acute human immunodeficiency virus infection
  • Next Article

    Changes and influence of microbiome in perioperative period